A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Inclusion Criteria: * Histologically proven Gastrointestinal Stomal Tumor (GIST) that is not amenable to standard therapy * Undergone screening and found to be ineligible for participation in ongoing SU011248 clinical studies * Patient judged to have potential to derive clinical benefit from SU011248 treatment by the treating physician * Failed prior treatment with imatinib mesylate, defined as either progression of disease or significant toxicity during treatment with imatinib mesylate that precluded further treatment * Male or Female, 18 years or older * Resolution of all acute toxicities of prior therapies * Adequate organ function Exclusion Criteria: * Symptomatic congestive heart failure, myocardial infarction, or coronary artery bypass graft in the last 6 months, or ongoing severe or unstable angina or any unstable arrhythmia requiring medication * Symptomatic central nervous system metastases * Serious acute or chronic illness * Current treatment on another clinical trial * Pregnant or breastfeeding.